1513 (1513) Fair Value & Analysis

Healthcare · Market cap HK$21.6B

1 1513 1513 · HK

PriceHK$23.88

Fair ValueHK$56.86

Upside+138.1%

Quality67/100

Evidence: Medium Range HK$42.65 – HK$71.08

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −3.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$23.40 – HK$37.44 · fair‑value band HK$42.65 – HK$71.08 · the HK$23.88 price screens below the HK$56.86 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1513 (1513) currently trades at HK$23.88, while our model-based Fair Value estimate is HK$56.86 — implying the stock looks roughly 138.1% undervalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 1513 generated revenue of HK$11.7B at a net margin of 16.8%. Revenue declined 9.7% year over year. It earns a return on equity of 15.1%. The balance sheet holds a net cash position of HK$5.5B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$11.7B

Revenue growth (YoY) -9.7%

Net margin 16.8%

Return on equity 15.1%

Free cash flow HK$2.5B FY2025

P/E ratio 9.5

More key figures

Operating margin 29.1%

EPS (TTM) HK$2.31

Dividend yield 6.0%

EPS growth (YoY) -8.5%

Net cash HK$5.5B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1513 reported revenue of HK$12.0B in FY2025 versus HK$12.1B in FY2021, a compound −0.1%/yr. Reported net income was HK$2.0B in FY2025, compounding +3.3%/yr from FY2021.

Revenue −0.1%/yr

FY21 HK$12.1B

FY22 HK$12.6B

FY23 HK$12.4B

FY24 HK$11.8B

FY25 HK$12.0B

Net income +3.3%/yr

FY21 HK$1.8B

FY22 HK$1.9B

FY23 HK$2.0B

FY24 HK$2.1B

FY25 HK$2.0B

Is 1513 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1513 (1513) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$56.86 versus a price of HK$23.88 — about +138% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1513?

Our model-based fair value for 1513 is HK$56.86 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$23.88.

What is the quality score of 1513?

1513 has a Quality Score of 67/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1513 (1513)?

1513 reported trailing-twelve-month revenue of about HK$11.7B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1513?

The net profit margin of 1513 is about 16.8%, meaning it keeps roughly 16.8% of revenue as net income. Based on the latest reported figures.

Does 1513 pay a dividend?

1513 currently shows a dividend yield of about 5.99% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.